PIERIS PHARMACEUTICALS INC's ticker is PIRS and the CUSIP is 720795103. A total of 73 filers reported holding PIERIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,442 | +80.0% | 8,196 | 0.0% | 0.00% | – |
| Q2 2023 | $1,357 | -95.4% | 8,196 | -72.8% | 0.00% | – |
| Q1 2023 | $29,368 | -87.0% | 30,090 | -86.2% | 0.00% | – |
| Q4 2022 | $226,561 | -83.0% | 217,847 | -81.2% | 0.00% | – |
| Q3 2022 | $1,330,000 | -39.2% | 1,156,290 | -1.0% | 0.00% | – |
| Q2 2022 | $2,186,000 | -40.1% | 1,168,413 | -2.9% | 0.00% | – |
| Q1 2022 | $3,648,000 | -29.7% | 1,203,713 | -12.3% | 0.00% | -100.0% |
| Q4 2021 | $5,187,000 | -42.2% | 1,372,495 | -21.0% | 0.00% | 0.0% |
| Q3 2021 | $8,981,000 | +39.9% | 1,737,126 | +3.6% | 0.00% | 0.0% |
| Q2 2021 | $6,419,000 | +204.8% | 1,675,969 | +104.6% | 0.00% | – |
| Q1 2021 | $2,106,000 | -1.5% | 819,176 | -4.2% | 0.00% | – |
| Q4 2020 | $2,138,000 | +596.4% | 854,932 | +476.8% | 0.00% | – |
| Q3 2020 | $307,000 | +52.0% | 148,209 | +127.6% | 0.00% | – |
| Q2 2020 | $202,000 | -77.9% | 65,113 | -83.7% | 0.00% | – |
| Q1 2020 | $912,000 | -68.9% | 400,233 | -50.7% | 0.00% | -100.0% |
| Q4 2019 | $2,936,000 | +240.2% | 811,211 | +220.6% | 0.00% | – |
| Q3 2019 | $863,000 | +637.6% | 253,055 | +922.8% | 0.00% | – |
| Q2 2019 | $117,000 | +31.5% | 24,741 | -7.4% | 0.00% | – |
| Q1 2019 | $89,000 | -69.1% | 26,706 | -75.4% | 0.00% | – |
| Q4 2018 | $288,000 | -60.4% | 108,353 | -16.6% | 0.00% | – |
| Q3 2018 | $727,000 | +13.4% | 129,910 | +2.8% | 0.00% | – |
| Q2 2018 | $641,000 | -90.6% | 126,341 | -87.4% | 0.00% | -100.0% |
| Q1 2018 | $6,829,000 | +239.1% | 1,001,258 | +275.2% | 0.00% | +100.0% |
| Q4 2017 | $2,014,000 | +57.3% | 266,825 | +20.1% | 0.00% | – |
| Q3 2017 | $1,280,000 | -3.6% | 222,229 | -15.4% | 0.00% | – |
| Q2 2017 | $1,328,000 | +33.1% | 262,579 | -31.6% | 0.00% | – |
| Q1 2017 | $998,000 | +94.9% | 383,834 | +5.3% | 0.00% | – |
| Q4 2016 | $512,000 | +276.5% | 364,368 | +390.2% | 0.00% | – |
| Q3 2016 | $136,000 | – | 74,330 | +74230.0% | 0.00% | – |
| Q2 2016 | $0 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 9,775,849 | $2,913,203 | 1.93% |
| Aquilo Capital Management, LLC | 3,303,190 | $984,351 | 0.89% |
| CM Management, LLC | 649,400 | $193,521 | 0.20% |
| BVF INC/IL | 20,609,863 | $6,141,739 | 0.17% |
| WEALTH EFFECTS LLC | 11,700 | $3,487 | 0.00% |
| NJ State Employees Deferred Compensation Plan | 30,000 | $8,940 | 0.00% |
| HUDSON VALLEY INVESTMENT ADVISORS INC /ADV | 14,000 | $4,172 | 0.00% |
| ACADIAN ASSET MANAGEMENT LLC | 962,358 | $286 | 0.00% |
| TWO SIGMA ADVISERS, LP | 24,400 | $7,271 | 0.00% |
| Tower View Wealth Management LLC | 1,000 | $0 | 0.00% |